Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1234)	6/29/2004 11:18:46 AM
From: Icebrg	Read Replies (1) \| Respond to of 1834

Neurocrine Biosciences initiated with "hold" Tuesday, June 29, 2004 9:24:06 AM ET Wells Fargo Securities NEW YORK, June 29 (New Ratings) - Analyst Eun Yang of Wells Fargo Securities initiates coverage of Neurocrine Biosciences (NBIX.NAS) with a "hold" rating. In a research note published this morning, the analyst mentions that the company's product, Indiplon, is in Phase III trials and is expected to be launched in early-2006. Neurocrine Biosciences is likely to gain substantial share in the insomnia market in the long term, given its marketing collaboration with Pfizer, the analyst says. The company's stock, however, lacks near-term catalysts, according to Wells Fargo Securities.